Who are the Institutional Holders in Travere Therapeutics Inc (TVTX)?

Travere Therapeutics Inc (NASDAQ: TVTX) is -7.68% lower on its value in year-to-date trading and has touched a low of $5.25 and a high of $23.18 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TVTX stock was last observed hovering at around $8.28 in the last trading session, with the day’s gains setting it 0.02%.

Currently trading at $8.30, the stock is -6.82% and -3.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.83 million and changing 0.24% at the moment leaves the stock -31.21% off its SMA200. TVTX registered -61.93% loss for a year compared to 6-month loss of -45.57%. The firm has a 50-day simple moving average (SMA 50) of $1.70 and a 200-day simple moving average (SMA200) of -$1.51.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -15.31% gain in the last 1 month and extending the period to 3 months gives it a 15.60%, and is -3.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.50% over the week and 6.16% over the month.

Travere Therapeutics Inc (TVTX) has around 462 employees, a market worth around $623.75M and $209.65M in sales. Profit margin for the company is -149.29%. Distance from 52-week low is 58.10% and -64.19% from its 52-week high. The company has generated returns on investments over the last 12 months (-46.00%).

Travere Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$1.26 with sales reaching $41.51M over the same period.The EPS is expected to grow by 60.00% this year, but quarterly earnings will post -8.10% year-over-year. Quarterly sales are estimated to shrink -25.70% in year-over-year returns.

238 institutions hold shares in Travere Therapeutics Inc (TVTX), with institutional investors hold 114.47% of the company’s shares. The shares outstanding are 75.15M, and float is at 70.90M with Short Float at 13.69%. Institutions hold 113.30% of the Float.

The top institutional shareholder in the company is Armistice Capital, LLC with over 7.45 million shares valued at $114.43 million. The investor’s holdings represent 9.93% of the TVTX Shares outstanding. As of Jun 29, 2023, the second largest holder is Deep Track Capital, Lp with 7.37 million shares valued at $113.2 million to account for 9.83% of the shares outstanding. The other top investors are Blackrock Inc. which holds 7.12 million shares representing 9.49% and valued at over $109.32 million, while Janus Henderson Group PLC holds 9.29% of the shares totaling 6.97 million with a market value of $107.01 million.

Travere Therapeutics Inc (TVTX) Insider Activity

A total of 8 insider transactions have happened at Travere Therapeutics Inc (TVTX) in the last six months, with sales accounting for 5 and purchases happening 3 times. The most recent transaction is an insider sale by Dube Eric M, the company’s CHIEF EXECUTIVE OFFICER. SEC filings show that Dube Eric M sold 19,122 shares of the company’s common stock on Feb 01 at a price of $8.70 per share for a total of $0.17 million. Following the sale, the insider now owns 0.35 million shares.

Travere Therapeutics Inc disclosed in a document filed with the SEC on Feb 01 that REED ELIZABETH E (SVP, GC & CORPORATE SECRETARY) sold a total of 4,764 shares of the company’s common stock. The trade occurred on Feb 01 and was made at $8.71 per share for $41495.0. Following the transaction, the insider now directly holds 76270.0 shares of the TVTX stock.

Still, SEC filings show that on Feb 01, ROTE WILLIAM E. (SENIOR VICE PRESIDENT, R&D) disposed off 4,764 shares at an average price of $8.71 for $41495.0. The insider now directly holds 80,720 shares of Travere Therapeutics Inc (TVTX).